BAK1 and acute myeloid leukemia: As venetoclax is a Bcl-2 inhibitor, it requires an apoptotic trigger to activate its function effectively, suggesting that agents like VPA, which induce Bax and Bak, are suitable partners in AML treatment (Figure 6).